ReviewBasic research in cardiology2016
Emerging role of liver X receptors in cardiac pathophysiology and heart failure.
Review in Basic research in cardiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 65 citations in OpenAlex.
- Pregnane X Receptor‒4β-Hydroxycholesterol Axis in the Regulation of Overweight- and Obesity-Induced Hypertension.Journal of the American Heart Association · 2022Trial
- Precision biomarker discovery in hypertension through explainable AI and proteomics.Journal of human hypertension · 2026Article
- Hypertension in Overweight and Obesity: Sex-Specific Role of 4β-Hydroxycholesterol.Journal of the American Heart Association · 2026Article
- Proteomic Signatures of Cardiac Dysfunction Among People With Diabetes: The Atherosclerosis Risk in Communities Study.Circulation. Heart failure · 2026Article
- GATA4-overexpressing BMSCs-derived exosome regulation of myocardial infarction in mice by key miRNA and apoptosis gene CLU.European journal of medical research · 2026Article
- Role of oxysterol 4β-hydroxycholesterol and liver X receptor alleles in pre-eclampsia.Annals of medicine · 2025Article
- Colonization withbioRxiv : the preprint server for biology · 2025Article
- Exploration of Conserved Human Adipose Subpopulations Using Targeted Single-Nuclei RNA Sequencing Data Sets.Journal of the American Heart Association · 2025Article
- Cyclodextrin reduces cholesterol crystal uptake by circulating monocytes in patients undergoing coronary angiography.PloS one · 2025Article
- Proteome-wide Characterization and Pathophysiology Correlation in Non-ischemic Cardiomyopathies.Korean circulation journal · 2024Article
- Liver X Receptor Agonist 4β-Hydroxycholesterol as a Prognostic Factor in Coronary Artery Disease.Journal of the American Heart Association · 2024Observational
- The role and therapeutic potential of SIRTs in sepsis.Frontiers in immunology · 2024Review
- Serum Proteomic Analysis of Peripartum Cardiomyopathy Reveals Distinctive Dysregulation of Inflammatory and Cholesterol Metabolism Pathways.JACC. Heart failure · 2023Article
- Brain nuclear receptors and cardiovascular function.Cell & bioscience · 2023Review
- Feline myocardial transcriptome in health and in hypertrophic cardiomyopathy-A translational animal model for human disease.PloS one · 2023Article
- Role of cellular retinol-binding protein, type 1 and retinoid homeostasis in the adult mouse heart: A multi-omic approach.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Article
- The liver X receptor agonist T0901317 reduces the inflammation of alveolar epithelial cells induced by polyhexamethylene guanidine through inhibition of the NFκB signaling pathway.Annals of translational medicine · 2021Article
- RNA binding Motif protein-38 regulates myocardial hypertrophy in LXR-α-dependent lipogenesis pathway.Bioengineered · 2021Article
- Review
- Multi-omic Analysis of Non-human Primate Heart after Partial-body Radiation with Minimal Bone Marrow Sparing.Health physics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liver X receptors (LXRs) are master regulators of metabolism and have been studied for their pharmacological potential in vascular and metabolic disease. Besides their established role in metabolic homeostasis and disease, there is mounting evidence to suggest that LXRs may exert direct beneficial effects in the heart. Here, we aim to provide a conceptual framework to explain the broad mode of action of LXRs and how LXR signaling may be an important local and systemic target for the treatment of heart failure. We discuss the potential role of LXRs in systemic conditions associated with heart failure, such as hypertension, diabetes, and renal and vascular disease. Further, we expound on recent data that implicate a direct role for LXR activation in the heart, for its impact on cardiomyocyte damage and loss due to ischemia, and effects on cardiac hypertrophy, fibrosis, and myocardial metabolism. Taken together, the accumulating evidence supports the notion that LXRs may represent a novel therapeutic target for the treatment of heart failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.